No Data
Mirum Pharmaceuticals To Showcase LIVMARLI Data From Its ALGS And PFIC Programs At The NASPGHAN Annual Meeting
Mirum Pharmaceuticals Is Maintained at Outperform by Leerink Partners
Leerink Partners Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $49
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $66
Mirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation From FDA
Express News | Mirum Pharmaceuticals Inc: Confirmatory Portion of Study Is Ongoing With Completion of Enrollment Expected in 2026
No Data
No Data